Piper Sandler has revised its price target for Sarepta Therapeutics (SRPT, Financial), reducing it from $182 to $110 while maintaining an Overweight rating on the stock. This adjustment reflects decreased sales projections for Sarepta's Elevidys, following insights from a survey conducted with 20 neurologists.
The survey aimed to assess the impact of a recent safety update regarding Elevidys on prescribing habits and market perception. The results revealed that while 40% of the surveyed neurologists indicated the safety incident had no effect on their prescribing practices, 60% reported a likely impact, leading to hesitancy in recommending the treatment.
Based on these findings, Piper Sandler anticipates a significant decline in Elevidys usage, projecting an average decrease of 14% for ambulatory and 24% for non-ambulatory cases for the remainder of 2025 and into the fiscal year 2026. These adjustments underline the uncertainty surrounding Elevidys’ future market performance amid safety concerns.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for Sarepta Therapeutics Inc (SRPT, Financial) is $155.09 with a high estimate of $209.00 and a low estimate of $70.00. The average target implies an upside of 188.32% from the current price of $53.79. More detailed estimate data can be found on the Sarepta Therapeutics Inc (SRPT) Forecast page.
Based on the consensus recommendation from 25 brokerage firms, Sarepta Therapeutics Inc's (SRPT, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Sarepta Therapeutics Inc (SRPT, Financial) in one year is $215.89, suggesting a upside of 301.36% from the current price of $53.79. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Sarepta Therapeutics Inc (SRPT) Summary page.
